These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36076082)

  • 1. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors.
    Weidenbacher PA; Waltari E; de Los Rios Kobara I; Bell BN; Morris MK; Cheng YC; Hanson C; Pak JE; Kim PS
    Nat Chem Biol; 2022 Nov; 18(11):1270-1276. PubMed ID: 36076082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
    Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
    Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes.
    Noy-Porat T; Makdasi E; Alcalay R; Mechaly A; Levy Y; Bercovich-Kinori A; Zauberman A; Tamir H; Yahalom-Ronen Y; Israeli M; Epstein E; Achdout H; Melamed S; Chitlaru T; Weiss S; Peretz E; Rosen O; Paran N; Yitzhaki S; Shapira SC; Israely T; Mazor O; Rosenfeld R
    Nat Commun; 2020 Aug; 11(1):4303. PubMed ID: 32855401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.
    Chiang CY; Chen MY; Hsu CW; Liu CY; Tsai YW; Liao HC; Yan JY; Chuang ZS; Wang HI; Pan CH; Yu CY; Yu GY; Liao CL; Liu SJ; Chen HW
    J Biomed Sci; 2022 Jun; 29(1):37. PubMed ID: 35681239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review].
    Chen Y; Lin J; Zheng P; Cao M; Jin T
    Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3173-3193. PubMed ID: 36151792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern.
    Du W; Hurdiss DL; Drabek D; Mykytyn AZ; Kaiser FK; González-Hernández M; Muñoz-Santos D; Lamers MM; van Haperen R; Li W; Drulyte I; Wang C; Sola I; Armando F; Beythien G; Ciurkiewicz M; Baumgärtner W; Guilfoyle K; Smits T; van der Lee J; van Kuppeveld FJM; van Amerongen G; Haagmans BL; Enjuanes L; Osterhaus ADME; Grosveld F; Bosch BJ
    Sci Immunol; 2022 Jul; 7(73):eabp9312. PubMed ID: 35471062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.
    Sankhala RS; Dussupt V; Chen WH; Bai H; Martinez EJ; Jensen JL; Rees PA; Hajduczki A; Chang WC; Choe M; Yan L; Sterling SL; Swafford I; Kuklis C; Soman S; King J; Corbitt C; Zemil M; Peterson CE; Mendez-Rivera L; Townsley SM; Donofrio GC; Lal KG; Tran U; Green EC; Smith C; de Val N; Laing ED; Broder CC; Currier JR; Gromowski GD; Wieczorek L; Rolland M; Paquin-Proulx D; van Dyk D; Britton Z; Rajan S; Loo YM; McTamney PM; Esser MT; Polonis VR; Michael NL; Krebs SJ; Modjarrad K; Joyce MG
    Structure; 2024 Feb; 32(2):131-147.e7. PubMed ID: 38157856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif.
    Fang Y; Sun P; Xie X; Du M; Du F; Ye J; Kalveram BK; Plante JA; Plante KS; Li B; Bai XC; Shi PY; Chen ZJ
    Sci Immunol; 2022 Oct; 7(76):eabp9962. PubMed ID: 35926067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.